Displaying One Session
Teaching Course
Fri, Sep 11, 2020
Invited Presentations
Invited Abstracts
Invited Presentations
Invited Abstracts
TC12.01 - Presentation 01 (ID 623)
Speakers
Authors
Presentation Number
TC12.01
Presentation Topic
Invited Presentations
Abstract
Abstract
Progressive MS represents the major unmet therapeutic need in MS, today. Our understanding od progressive MS, as a part of the full spectrum of MS, has expanded considerably. In order to better treat progressive MS we must understand how this phase of the disease develops and how to recognize the progressive course. In this teaching course we will review the definitions of progressive MS and how this is a subset of worsening MS, what the role of inflammation plays, how progression interacts with MS disease activity and how all this could lead to better therapies.
Invited Presentations
Invited Abstracts
TC12.02 - Treatment of Progressive MS (ID 624)
Speakers
Authors
Presentation Number
TC12.02
Presentation Topic
Invited Presentations
Abstract
Abstract
The treatment of progressive multiple sclerosis (MS) is probably one of the greatest challenges facing the MS community. The need is great for this most disabling form of MS but the challenges are considerable, not least the poor understanding of the mechanisms underpinning progression which in turn creates problems in defining the clinical phenotype and, more importantly, identifying potential targets for effective treatment.The recent licensing of two agents one for primary (ocrelizumab) and one for secondary progressive MS (siponimod) has gone some way to offset the preceding negative results of trials of agents such as natalizumab and fingolimod. The treatment effect is modest for both (21-25%), perhaps implicating their particular modes of action. The armamentarium has been increased in the USA by the FDA’s ruling that agents that are effective in relapsing forms of MS should also be applied to patients with active (continuing to have relapses) secondary progressive MS
The importance of targeting neuroprotection and repair cannot be over-estimated and results of studies in these areas have been mixed to date. Nonetheless, some progress is being made and with the concerted efforts of organisations such as the Progressive MS Alliance, it is hoped that over the next five years we will have even more effective treatments for progressive MS.